Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

clinical investigation of the TLR7 mechanism in HCV by taking ANA773 into a clinical trial under a two-part protocol designed to test ANA773 in both healthy volunteers and patients with HCV. In October, Anadys completed dosing in healthy volunteers. Subjects received a single dose followed by four doses taken every other day, at levels from 200 mg to 1600 mg (with six subjects receiving active and two receiving placebo in each dose cohort). No serious adverse events were reported. Biomarker induction indicative of immune activation was seen in a majority of subjects beginning at 800 mg. Some side effects commonly seen with interferon treatment, including fever and chills, were observed at higher doses, with the frequency and intensity of interferon-like side effects increasing with dose. One subject at the 1200 mg dose and two subjects at the 1600 mg dose discontinued from the trial before completion of dosing. Anadys expects to initiate Part B of the study in HCV patients within the next few weeks. Patients in the first cohort will receive 800 mg of ANA773 every other day for 28 days. Doses for subsequent cohorts will be selected based on viral load and tolerability data from the 800 mg cohort.

-- Phase I Clinical Trial of ANA773 in Oncology. Anadys continues to enroll patients in an ongoing Phase I clinical trial of ANA773 in oncology and has now completed enrollment in the third cohort.

Webcast of Conference Call

Anadys will host a conference call at 5:00 p.m. EDT today to discuss its third quarter financial results and highlights and to provide an update on its development programs. A live webcast of the call will be available online at http://www.anadyspharma.com. A telephone replay will also be available approximately one hour after completion of the call. To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 86226986. The webcast and t
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 21, 2014 (PRWEB) July 23, 2014 ... at Rutgers University. , The goal of ... across the full spectrum of scientists working in ... and development topics that represent the most promising ... programmed to:,     Provide faculty and ...
(Date:7/22/2014)... WASHINGTON D.C., June 22, 2014 Even within a phylum ... fly is distinguished among other arthropods for its cruelty -- ... and Central America, the fly is a most predatory sort ... male cricket, deposits a smear of larvae, and leaves its ... inside out. , None of this would be possible ...
(Date:7/22/2014)... Vibrate a solution of rod-shaped metal nanoparticles in water ... like tiny drill bits. Why? No one yet knows ... and Technology (NIST) have clocked their speedand it,s fast. ... rotate 10 times faster than any nanoscale object submerged ... dizzying rate has opened up the possibility that they ...
(Date:7/22/2014)... , July 22, 2014   BioTE ... therapy using natural, bio-identical hormone pellets, today announced ... MD to the company.   Dr. Rouzier is joining ... physician.      Dr. Rouzier was residency ... UCLA and is a board certified emergency physician ...
Breaking Biology Technology:The 2014 NJ Symposium on Biomaterials Science Earns Society for Biomaterials Endorsement 2Fly-inspired sound detector 2Fly-inspired sound detector 3Fly-inspired sound detector 4NIST shows ultrasonically propelled nanorods spin dizzyingly fast 2Dr. Neal Rouzier Joins BioTE Medical 2Dr. Neal Rouzier Joins BioTE Medical 3
... work showing how nanowires carved in impurity-laden diamond ... developed a scalable manufacturing process to craft arrays ... photon control. The development supports efforts to ... stage for diamond-based microchips. Additionally, the technology ...
... 2011 Applied Precision is proud to announce ... super-resolution microscopy system at McGill University in Montreal, ... is a super-resolution microscope utilizing proven three-dimensional structured ... in volume resolution and outstanding widefield imaging capabilities. ...
... Ohio, Oct. 18, 2011 Minimally Invasive Devices, Inc ... new product, FloShield PLUS , utilizing the novel Flo-X ... of the end of the laparoscope without removal from the ... MID,s FloShield laparoscopic visualization system. In the first 19 FloShield ...
Cached Biology Technology:Diamonds, silver and the quest for single photons 2Diamonds, silver and the quest for single photons 3Applied Precision Announces the 25th Installation of Its DeltaVision OMX Super-Resolution Microscope at McGill University 2
(Date:7/23/2014)... Tracking of blue whales by satellite over a 15-year ... whales consistently return to feed in specific locations each ... in the open-access journal PLOS ONE by ... data may be used to mitigate human threats to ... has been slow to recover since the establishment of ...
(Date:7/23/2014)... cystic fibrosis patients, scientists at the UNC School of ... that a new CF drug counteracts the intended beneficial ... published today in the journal Science Translational Medicine ... and loses its ability to function properly when in ... several insights into how novel CF pharmacotherapies could be ...
(Date:7/23/2014)... , , , , , ... , , , , ... diseases and extend healthy lifespan. The idea, they argue, would be to target the... , , ... , , , , , ... , , , , , , , Medicine ...
Breaking Biology News(10 mins):Blue whales' dangerous feeding grounds 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 3UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 4Strategy proposed for preventing diseases of aging 2Strategy proposed for preventing diseases of aging 3Strategy proposed for preventing diseases of aging 4Strategy proposed for preventing diseases of aging 5
... several proteins in mice that might act as biomarkers ... step to finding a more reliable way to detect ... teenagers use illegally to boost muscle and reduce fat. ... San Francisco today, scientists John Kopchick and Juan Ding ...
... the White House must be enhanced so that the ... nationfrom energy and the environment, to national security, and ... collaborate internationally. The report,s primary recommendations are that: ... respected leader to be Assistant for Science and Technology ...
... 2008 Mary Tyler Moore, the Juvenile Diabetes Research ... M.D., presented the sixth annual "Excellence in Clinical Research ... annual conference today in Washington, DC. The recipients ... director of the JDRF Gene Therapy Center for Diabetes ...
Cached Biology News:Scientists find potential protein biomarkers for growth hormone 2White House science office needs upgrade 2White House science office needs upgrade 3Florida researchers receive JDRF 'Excellence in Clinical Research Award' 2